Oral contraceptives and cervical carcinoma.
In a case-control study, 689 consecutive patients with cervical carcinoma were studied for their use of oral contraceptives. The control patients were matched for age, ethnic origin, age at first pregnancy, age at first coitus, and socioeconomic status. There was no significant difference between case and control subjects in the duration or oral contraceptive use, the type of estrogen used, or the years in which oral contraceptives were used. The mean duration of oral contraceptive use was 30.9 months by the case subjects and 30.2 months by the control subjects.
D000293:Adolescent; D000328:Adult; D003267:Contraception / Q000379:methods; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008656:Mestranol / Q000009:adverse effects; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced*
D003276:Contraceptives, Oral; D003280:Contraceptives, Oral, Synthetic; D004997:Ethinyl Estradiol; D008656:Mestranol